Risankizumab in severe asthma: A Phase IIa, placebo-controlled study

C. Brightling (Leicester, United Kingdom), P. Nair (Hamilton, Canada), R. Louis (Liege, Belgium), D. Singh (Manchester, United Kingdom)

Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Session: Asthma pharmacology: clinical trials and mechanistic insights
Session type: Oral Presentation
Number: 3699

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Brightling (Leicester, United Kingdom), P. Nair (Hamilton, Canada), R. Louis (Liege, Belgium), D. Singh (Manchester, United Kingdom). Risankizumab in severe asthma: A Phase IIa, placebo-controlled study. 3699

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: